FDA Approves Moderna's mRNA Flu Vaccine for Older Adults

Why it matters locally: The approval of Moderna's mRNA flu vaccine will directly impact Pennsylvania's healthcare system and its substantial older adult population, providing a new option for influenza prevention. Healthcare providers across the state will need to integrate this new vaccine into their public health strategies.

---

The Food and Drug Administration (FDA) has approved Moderna's mRNA-based influenza vaccine, mFlusiva. This approval specifically covers adults aged 50 and older. mFlusiva represents a new type of flu shot entering the market. Moderna developed the vaccine using messenger RNA (mRNA) technology. This technology differs from traditional vaccine methods, which often use inactivated or weakened forms of the virus. Regulators granted approval for mFlusiva following a review of clinical data. The vaccine aims to protect against seasonal influenza. The target demographic for this shot includes individuals at higher risk of complications from the flu.